Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest small cell lung cancer Stories

2014-03-24 23:27:51

Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancer announced today that P2045, the Company's lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). Orphan...

2013-10-24 08:34:57

SAN FRANCISCO and BUFFALO, N.Y., Oct. 24, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and Roswell Park Cancer Institute (RPCI) announced today that the first patients have been dosed in a phase II investigator-sponsored study of etirinotecan pegol in patients with relapsed or refractory Small-Cell Lung Cancer (SCLC). The study is being conducted at Roswell Park under the direction of Alex Adjei, M.D., Ph.D., F.A.C.P., Senior Vice President for Clinical Research and Chair of the...

2013-08-01 23:22:59

MarketResearchReports.Biz announces addition of new report “Small-Cell Lung Cancer - Pipeline Review, H2 2013” to its database. Visit - http://www.marketresearchreports.biz/analysis-details/small-cell-lung-cancer-pipeline-review-h2-2013. Albany, New York (PRWEB) August 01, 2013 Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for...

35f3a691ee434334c1248708e09e4147
2011-07-19 13:05:00

Cancer biologists at MIT have identified a new lung cancer gene that drives the spread of the deadly condition. MIT reported that a major challenge for cancer biologists is determining which genetic mutations found in a cancer cell are most important for driving the cancer's spread. The scientists used a new technique called whole-genome profiling to pinpoint the gene that drives progression of small cell lung cancer, which accounts for about 15 percent of lung cancer cases. Alison Dooley,...

2011-05-12 07:00:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan. Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of...

2010-06-05 15:30:00

SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC). Dr. Tudor Eliade Ciuleanu, M.D., Ph.D., of Institute of Oncology, Cluj-Napoca, Romania and an investigator for the SPEAR...

2010-05-10 08:10:00

SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that data from the Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small cell lung cancer (SCLC) has been accepted for an oral presentation during the American Society of Clinical Oncology (ASCO) 2010...

2010-04-30 12:40:40

2nd European Lung Cancer Conference A new meta-analysis reported at the second European Lung Cancer Conference shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy. Patients treated with hyperfractionated or accelerated radiotherapy regimens are given their treatments more frequently, and over a shorter period of time. The benefit of doing this has been in...

2010-01-14 13:06:25

MicroRNAs are key to identifying patients resistant to 'first-line' chemotherapy Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy. The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, will be presented today in San Diego at a joint conference of the American Association for Cancer Research...

2009-11-30 08:00:00

NOVATO, Calif., Nov. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U. Also, in October 2009, the Committee for Medicinal Products for Human Use of the European Medicines...